Daniel A. Pryma

Hospital of the University of Pennsylvania — United States

Medicine · Health Sciences

42h-index8.2kcitations297works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(70), Medical Imaging Techniques and Applications(64), Radiopharmaceutical Chemistry and Applications(60), PARP inhibition in cancer therapy(40), Radiomics and Machine Learning in Medical Imaging(36)

Publications297 total

Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy
The Oncologist·2026Open Access
Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma
JAMA Otolaryngology–Head & Neck Surgery·2026Open Access
Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy
Journal of Nuclear Medicine·2025· 1 cited
Abstract A029: PARP-targeted alpha therapy for the treatment of PARP inhibitor resistant ovarian cancer
Cancer Research·2025
Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
Abstract P2-07-04: [18F]FluorThanatrace PET imaging correlates with response to PARP inhibitors in breast cancer: a pilot study
Clinical Cancer Research·2025
PARP1-targeted alpha therapy enhances target expression
EJNMMI Research·2025Open Access
[18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer
Communications Medicine·2025· 5 citedOpen Access
A biorthogonal chemistry approach for high-contrast antibody imaging of lymphoma at early time points
EJNMMI Research·2025· 1 citedOpen Access
Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2025
[<sup>18</sup>F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [<sup>18</sup>F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status
Journal of Nuclear Medicine·2024· 2 citedOpen Access
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate–Ribose) Polymerase-1–Targeted<sup>18</sup>F-Fluorthanatrace PET in Breast Cancer
Journal of Nuclear Medicine·2024· 3 citedOpen Access
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer
Journal of Clinical Oncology·2024· 29 citedOpen Access
Cardiac Neuroendocrine Tumor Metastases on<sup>68</sup>Ga-DOTATATE PET/CT: Identification and Prognostic Significance
Journal of Nuclear Medicine·2024· 5 citedOpen Access
53 (PB041): PARP-targeted theranostic radiopharmaceutical therapy for drugresistant ovarian cancer
European Journal of Cancer·2024
The Lancet Oncology Commission: Radiotherapy &amp; Theranostic Services in LMICs: Minding &amp; Mending the Gaps
International Journal of Radiation Oncology*Biology*Physics·2024· 2 cited
Relationship of Ketosis With Myocardial Glucose Uptake Among Patients Undergoing FDG PET/CT for Evaluation of Cardiac Sarcoidosis
Circulation Cardiovascular Imaging·2024· 8 cited
A general approach to reduce off-target radioactivity in vivo via Tetrazine-Knock-Out (TKO)
2024Open Access
Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy
Clinical Genitourinary Cancer·2024· 2 citedOpen Access
Theranostics in Neuroendocrine Tumors
The Cancer Journal·2024· 8 cited
page 1 of 15Next →

Frequent Co-authors

David A. Mankoff(10), Robert H. Mach(7), Mehran Makvandi(6), Ramesh Rengan(5), Chaitanya Divgi(5), Steven M. Larson(5), Michael D. Farwell(5), Neeta Pandit‐Taskar(4), Achim A. Jungbluth(4), John L. Humm(4), Lloyd J. Old(4), Jacob G. Dubroff(4), Thomas A. Hope(4), Kuiying Xu(4), Jorge A. Carrasquillo(4), Charles B. Simone(4), Corey J. Langer(4), Amit Maity(3), Rosemarie Mick(3), Stephen M. Hahn(3)